1. Bello N, Mosca L. Epidemiology of Coronary heart disease in Women. Progr Cardiovasc Dis 2004; 46: 287–95.
2. Терещенко С.Н., Ускач Т.М., Косицина И.В. и др. Особенности сердечно-сосудистых заболеваний и их лечение у женщин. Кардиология. 2005; 1: 98–102.
3. Green LA, Ruffin VT. Differences in management of suspected myocardial infarction in men and women. J Fam Pract 1993; 36: 389–93.
4. Simon T, Mary-Krause M, Cambou JP et al. Impact of age and gender on in-hospital and late mortality after acute myocardial infarction: increased early risk in younger women: results from the French nation-wide USIC registries. Eur Heart J 2006; 27: 1282–8.
5. Hunt KJ, Resendez RG, Williams K et al. National cholesterol education program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110: 1251–7.
6. Diabetes, Pre-diabetes and Cardiovascular diseases. 2007. Task Force. Eur Heart J 2007; 9 (Suppl. C): 1–74.
7. Мамедов М.Н. Нарушение толерантности к глюкозе: кто и как должен лечить? Кардиоваск. тер. и профилак. 2005; 4 (6): 89–96.
8. Chiasson J-L, Josse RG, Gomis R et al. Acarbose treatment and the risk od cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. Jama 2003; 290: 486–94.
9. Labrid C. Cellular disorders induced by ischemia. The effect of trimetazidine. Presse Med 1986; 15: 1754–7.
10. Kantor PF, Lucien A, Kozak R et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. J Circ Res 2000; 86: 580–8.
11. Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project--Free Radicals. Eur Heart J 2000; 21: 1537–46.
12. Iyengar SS, Rosano G. Effect of antianginal drugs in stable angina jn predicted mortality risk after surviving a myocardial infarction. Am J Cardiovasc Drugs 2009; 9: 293–7.
13. Ulgen MS, Akdemir O, Toprak N. The effects of trimetazidine on heart rate variability and signal-averaged electrocardiography in early period of acute myocardial infarction. Int J Cardiol 2001; 77: 255–62.
14. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability. Standards of measurement, physiologic interpretation, and clinical use. Circulation 1996; 93: 1043.
15. Lopaschuk GD. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis 2001; 12 (Suppl. 1): S8–11.
16. Лупанов В.П. Триметазидин МВ у больных с ишемической болезнью сердца (обзор). Cons. Med. 2010; 1: 5–11.